# US 2026/0097130 A1 · Method for treating neurodegenerative diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0097130 A1
- Document ID: US20260097130A1
- Status: Published application
- Kind: A1
- Application number: 19/406,217
- Filed: 2025-12-02
- Published: 2026-04-09
- Earliest claimed: 2023-06-05
- Assignees: Suntec Medical, Inc.
- Applicants: Suntec Medical, Inc.
- Inventors: Chun-Ting Cheng; Kuo-Liang Hou; Pauline Ying Lau
- Web page: https://patentgrep.com/patent/US20260097130A1

## CPC

- A61K 47/55: the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 9/5146: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides}
- A61K 31/353: 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61K 47/61: the organic macromolecular compound being a polysaccharide or a derivative thereof
- A61K 47/6803: {Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates}
- A61K 47/6907: {the form being a microemulsion, nanoemulsion or micelle}
- A61K 47/6935: {the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol}
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- C07K 16/32: against translation products of oncogenes
- A61K 2039/505: {comprising antibodies}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/74: Inducing cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention provides a method of treating neurodegenerative diseases. The method comprises the step of administering to a subject in need thereof an effective amount of a polymer-flavonoid conjugate, or a nanocomplex having an outer shell comprising one or more polymer-flavonoid conjugates and optionally an inner shell comprising one or more flavonoid oligomer and a drug such as anti-CD3 or anti-CD33 encapsulated within the shells. The present method brings therapeutic effective materials through blood-brain barrier to treat neurodegenerative diseases. The present method is effective to treat neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Lewy body dementia and Huntington's disease.

## Claims

### Claim 1

A method of treating a neurodegenerative disease, comprising the step of administering to a subject in need thereof an effective amount a nanocomplex having (a) an outer shell comprising one or more polymer-flavonoid conjugates, (b) optionally an inner shell comprising one or more flavonoid oligomer, and (c) anti-CD3 antibody or anti-CD33 antibody encapsulated within the shell or shells;
wherein the flavonoid is EGCG, EC, EGC, or ECG, as shown in the structures below:
the polymer is a hydrophilic polymer having a molecular weight of 1,000 to 100,000 daltons, and is selected from the group consisting of: poly(ethylene glycol) (PEG), hyaluronic acid, dextran, polyethylenimine, poloxamers, povidone, D-alpha-tocopheryl, and polyethylene glycol succinate;
the flavonoid oligomer comprises 2-20 flavonoids of EGCG, EC, EGC, or ECG;
the neurodegenerative disease is selected from the group consisting of: Alzheimer's disease, Parkinson's disease, Lewy body dementia and Huntington's disease.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the method reduces anti-CD3 toxicity, promotes neuron cell proliferation, prevents neuron cell death, reduce neuron oxidative stress, polarizes microglia from M1 to M2 status, and/or reduce abnormal protein aggregation.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the neurodegenerative disease is Alzheimer disease.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the neurodegenerative disease is Parkinson's disease.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the neurodegenerative disease is Lewy body dementia.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the neurodegenerative disease is Huntington's disease.

### Claim 7 (depends on 1)

The method according to claim 1, wherein an anti-CD3 antibody is encapsulated within the shell or shells.

### Claim 8 (depends on 1)

The method according to claim 1, wherein an anti-CD33 antibody is encapsulated within the shell or shells.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the flavonoid is EGCG, and the hydrophilic polymer is PEG.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the neurodegenerative disease is Alzheimer's disease.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the neurodegenerative disease is Parkinson's disease.